Conclusion:
Immune targeted therapies can be a promising outlook for the treatment of COVID-19 infection. Until now, antiviral agents were not particularly successful in controlling this massive pandemic, and there is also strong evidence of dysregulated immune responses during this infection. So, agents with immunomodulatory properties that can reinforce the immune system to clear the virus by itself can take into consideration. The CD200: CD200-R inhibitors, IFN I & III, and immune checkpoint inhibitors might be the plausible immunomodulator options.
Clinical decisions about using these agents must be based on the patient’s immunological status, cost & availability, and specifically, the results of ongoing clinical studies on their safety and efficacy for the current purpose.
Fig.1 shows a summary of possible immune targeted therapies for COVID-19 infection.